Guggenheim Maintains Buy on Cogent Biosciences, Raises Price Target to $52
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
Guggenheim analyst Michael Schmidt maintains Cogent Biosciences (NASDAQ:COGT) with a Buy and raises the price target from $45 to $52.
Guggenheim analyst Michael Schmidt maintains Cogent Biosciences (NASDAQ:COGT) with a Buy and raises the price target from $45 to $52.